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Innovative effective treatment for haematological 
malignancies (HMs) have become available since 2000’s. 
 
The aim of this study was to estimate time trends in 
population-based survival for 11 lymphoid and myeloid 
malignancies, in particular for diffuse large B-cell 
lymphoma (DBLCL), follicular lymphoma (FL), chronic 
myeloid leukaemia (CML) and acute promyelocytic 
leukaemia (APL). 















The increased survival over time is likely attributable linked to the diffusion of targeted and other new effective treatments. 
The large differences in cancer survival across Europe suggest inequalities in the provision of care and the availability of new 
treatments. 
Population-based high resolution studies, collecting data on morphology, treatments and stage, can provide evidence of the above 
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Paper published in Lancet Oncol 2014;15:931-42 
* Not age-standardised estimates 
102 European cancer registries (CRs) 
recording adult HMs cases 
35 CRs had continous incident data 
from 1992 to 2007 
5 CRs excluded because: 
>14% DCO or autopsy 
>30% cases not microscopically 
veriefied 
30 CRs included in the study 
Analyses by age 
at diagnosis 
Analyses by  
European area 
• 5-year relative survival 
• hybrid approach 
• trends by 3-year periods (1997-
99, 2000-02, 2003-05, 2006-08) 
 
